OS Therapies Inc (OSTX)
AMEXHealth CareBiotechnologySnapshot 2026-11-05
$0.98-14.77%
Close 2026-11-05 · 1-day change
AMEXHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · OSTX
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Medicines and Healthcare products Regulatory Authority (MHRA), the European Medicines Agency (EMA) and the Australian Therapeutic Goods Administration (TGA) in the fourth quarter of 2026.
Stated in 1 of 1 supplied quarters. Management reported: “and Europe for OST-HER2 in the prevention of delay of recurrent, fully resected, pulmonary metastatic osteosarcoma in the second half of 2026 New York, NY, April 2, 2026 – OS Therapies, Inc. (NYSE-A: OSTX) (“OS Therapies” or “the Company”), the world leader in gene-edited, listeria-based cancer immunotherapies, today announced it that it has completed a $5.25 million registered direct offering of common stock (or pre-funded warrants in lieu thereof) and warrants, with participation primarily from high-net-worth investors who have invested in several of the Company’s prior financing rounds.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13498).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“and Europe for OST-HER2 in the prevention of delay of recurrent, fully resected, pulmonary metastatic osteosarcoma in the second half of 2026 New York, NY, April 2, 2026 – OS Therapies, Inc. (NYSE-A:…”
The Company expects to use the net proceeds to support regulatory filings and commercial preparation activities related for Herlystic™ in the prevention or delay of recurrence in fully resected, pulm…
Stated in 1 of 1 supplied quarters. Management reported: “subsidiary, expected to provide cash runway into 2027 ● Company expects to receive approvals in the U.S., U.K.” “The Company expects to use the net proceeds to support regulatory filings and commercial preparation activities related for Herlystic™ in the prevention or delay of recurrence in fully resected, pulmonary metastatic osteosarcoma in the U.S., U.K., European Union (EU) and Australia (the “Human Metastatic Osteosarcoma Program”), and for general corporate purposes.” Operating income was $-8.576 million in 2026-Q2.
“subsidiary, expected to provide cash runway into 2027 ● Company expects to receive approvals in the U.S., U.K.”
Mr. Clem now leads the Company’s U.S., U.K., and European commercialization strategy and launch planning for Herlystic™ (OST-HER2; daznelimgene lisbac), the Company’s investigational immunotherapy fo…
Stated in a supplied disclosure. Management reported: “Mr. Clem now leads the Company’s U.S., U.K., and European commercialization strategy and launch planning for Herlystic™ (OST-HER2; daznelimgene lisbac), the Company’s investigational immunotherapy for the prevention or delay of recurrence in patients with fully resected, pulmonary metastatic osteosarcoma.” “My near-term focus will be building a disciplined, patient-centered launch plan and the commercial capabilities in the U.S. when the FDA approves the therapy, while the Company advances its regulatory work internationally,” said Mr. Clem.”
Use available funding to support initiation of the confirmatory trial, including activation of an initial site in Australia.
Secure regulatory approvals for OST-HER2 in the U.S., U.K., and Europe by end of 2026 to enable market access and potential Priority Review Voucher eligibility.
Over the trailing year it converted 0.55x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
35 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated volatile grew net income 45% of the time over the next year (vs 45% for the rest of the cohort, n=10076).
Not investment advice. As of 2026-11-05.